According to GSK, Eltrombopag is indicated for adult chronic ITP splenectomised patients who are refractory (have not responded) to other treatments, such as corticosteroids and immunoglobulins. Eltrombopag may also be considered as second-line treatment for adult non-splenectomised patients where surgery is contraindicated.
Eltrombopag was discovered as a result of a research collaboration between GSK and Ligand Pharmaceuticals, and is developed by GSK.